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Background: Multiple myeloma (MM) is a fatal plasma cell malignancy exhibiting enhanced glucose consumption
associated with an aerobic glycolytic phenotype (i.e., the Warburg effect). We have previously demonstrated that
myeloma cells exhibit constitutive plasma membrane (PM) localization of GLUT4, consistent with the dependence
of MM cells on this transporter for maintenance of glucose consumption rates, proliferative capacity, and viability.
The purpose of this study was to investigate the molecular basis of constitutive GLUT4 plasma membrane
localization in MM cells.
Findings: We have elucidated a novel mechanism through which myeloma cells achieve constitutive GLUT4
activation involving elevated expression of the Rab-GTPase activating protein AS160_v2 splice variant to promote
the Warburg effect. AS160_v2-positive MM cell lines display constitutive Thr642 phosphorylation, known to be
required for inactivation of AS160 Rab-GAP activity. Importantly, we show that enforced expression of AS160_v2 is
required for GLUT4 PM translocation and activation in these select MM lines. Furthermore, we demonstrate that
ectopic expression of a full-length, phospho-deficient AS160 mutant is sufficient to impair constitutive GLUT4 cell
surface residence, which is characteristic of MM cells.
Conclusions: This is the first study to tie AS160 de-regulation to increased glucose consumption rates and the
Warburg effect in cancer. Future studies investigating connections between the insulin/IGF-1/AS160_v2/GLUT4 axis
and FDG-PET positivity in myeloma patients are warranted and could provide rationale for therapeutically targeting
this pathway in MM patients with advanced disease.Findings
The Rab-GTPase activating protein (Rab-GAP) AKT
substrate of 160 kDa (AS160) plays a critical role regu-
lating the tethering and fusion of GLUT4-containing
vesicles with the plasma membrane [1,2]. AS160 is the
product of the gene TBC1D4, which belongs to the
TBC1 (Tre-2, BUB2p, and Cdc16p) gene family of Rab-
GAPs. AS160 contains numerous phosphorylation sites,
including the critical residues Ser588 and Thr642 [1]. In
the presence of activating stimuli, phosphorylation of
AS160 by the AGC kinases such as RSK1, SGK1, or* Correspondence: mala@northwestern.edu
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reproduction in any medium, provided the orPKB/AKT [3], leads to inactivation of the Rab-GAP do-
main to allow GTP-loaded Rab proteins to ferry GSVs to
the PM. AS160 also functions as a positive regulator of
GLUT4 trafficking [4]. Specific N terminal domains in
AS160 facilitate interaction of AS160 with PM phospho-
lipids, bringing GLUT4-GSVs in proximity to the PM.
The proximity of AS160 to active kinases such as AKT
in the PM promotes phosphorylation and inactivation of
AS160-Rab GAP activity facilitating insertion of these
proximal GLUT4-GSVs into the PM [4].
Interestingly, a novel AS160 splice variant was recently
discovered (termed AS160_v2 or AS160 variant 2) which
lacks exons 11 and 12 and exhibits a broad expression
profile in human tissues [5]. The lack of these coding se-
quences appears to imbue the AS160_v2 protein with an
increased permissiveness toward GLUT4 trafficking toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phosphorylation sites or protein subdomains [5]. Im-
portantly, it has been demonstrated that ectopic expres-
sion of AS160_v2 in rat L6 myotubes enhances GLUT4
PM localization and increases glucose consumption
rates by 30% to 40% during insulin or IGF-1 treatment
[5]. Given the importance of AS160 in the regulation of
GLUT4 trafficking, the identification of a splice variant
of AS160 displaying a diminished propensity for GLUT4
retention, and the knowledge that the AGC kinases
AKT [6], RSK [7], and SGK [8] are constitutively active
in myeloma, we sought to determine whether AS160Figure 1 AS160_v2 is selectively upregulated in a subset of multiple
in NBL and a panel of 8 MM cell lines assessed by qRT-PCR. Primers directe
were used in the quantitative RT-PCR analysis. Bars represent mean ± SD o
generated with primers flanking exons 11 and 12 from cDNA of MM.1S, KM
vector containing full-length AS160 cDNA as template is included as a con
AS160_v2 abundance in NBL (D), MM cell lines (E), and MM patient sample
cells) were excluded.deregulation contributes substantively to the basal acti-
vation of GLUT4, that we have previously demonstrated
in myeloma cells [9].
AS160_v2 is expressed in several multiple myeloma cell
lines but is absent in normal B lymphocytes
Quantitative RT-PCR performed on a panel of multiple
myeloma (MM) cell lines revealed an up-regulation of
AS160 at the transcript level in JJN3, KMS11, L363,
RPMI8226, and H929 cells (Figure 1A), while MM.1S,
U266, and INA6 exhibit low levels of AS160 mRNA ex-
pression, comparable to normal B lymphocytes (NBL).myeloma cell lines and patient samples. (A) AS160 transcript levels
d towards exon 1, common to full length and AS160_v2 transcripts
f three repeats; (B) Agarose gel electrophoresis of PCR products
S11, JJN3, and L363 cell lines. PCR product from a reaction using a
trol; (C) Analysis of AS160 transcript abundance in the JJN3 cell line.
transcriptomes (F). Samples lacking AS160_v2 (12 of 82 normal B
Figure 2 AS160_v2 is phosphorylated in myeloma cells
and introduction of a phospho-deficient AS160 mutant
impairs constitutive GLUT4 plasma membrane localization.
(A) Immunoblot analysis of AS160 protein levels in MM cell lines;
(B) Immunoblot analysis of pThr642 AS160 protein levels in MM
cell lines; (C) GLUT1 and GLUT4 localization in MM.1S cell line
transiently co-transfected with GFP and either empty vector (pcDNA)
or full-length AS160-4P; 48 h after transfection, GFP-positive cells
were sorted and imaged for GLUT1 and GLUT4 via confocal
immunofluorescence microscopy. Images and immunoblots are
representative of three individual repeats.
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PCR analysis. A region of the AS160 transcript spanning
exons 11 and 12 was amplified from cDNA generated
from MM cell lines and full-length AS160 cDNA, as a
control. The predominant PCR product amplified from
the MM cell line cDNA was significantly shorter than
the product from the vector; consistent with the 189 bp
length of exons 11 and 12 (Figure 1B). Sequencing of
the PCR products confirmed the absence of exons 11
and 12 [5]. Furthermore, RNA-Seq transcriptomic ana-
lysis of the JJN3 myeloma cell line confirmed complete
sequence identity with the AS160_v2 reference sequence
[5]. In addition to the full length AS160 sequence and
AS160_v2 sequences, six additional AS160 transcripts
have been identified and deposited in the NCBI data-
base. We quantified the reads associated with the AS160
full-length, AS160_v2 splice isoform and additional tran-
scripts and found that AS160_v2 constitutes 94.8% of all
transcripts associated with this gene in the JJN3 cell line
(Figure 1C). Moreover, analysis of 60 other MM cell line
transcriptomes demonstrated that AS160_v2 accounted
for greater than 95% of all AS160 expression (Figure 1E)
in the vast majority of the tested cell lines.
Importantly, in an analysis of MM patient sample
transcriptomes we found that 38 of 82 (46%) of the sam-
ples demonstrated greater than 75% of AS160 transcripts
to be AS160_v2 (Figure 1F). Analysis of 11 normal B cell
transcriptomes revealed significantly lower AS160_v2
expression (~38% to 55% of total transcript abundance,
Figure 1D). A t-Test comparing myeloma patient sam-
ples and NBL samples for AS160_v2 abundance demon-
strated that the expression of AS160_v2 is significantly
higher in the MM cells (ρ = 2.5×10-43). NBLs and MM
patient samples and cell lines did not express full-length
AS160 transcript (from analysis of the RNA-Seq data
sets – data not shown) normally expressed in muscle
and adipose tissue.
AS160_v2 is phosphorylated in MM cell lines and
GLUT4 is removed from the PM by expression of a
non-phosphorylatable, full length AS160 protein
Immunoblot analysis revealed that AS160_v2 is consti-
tutively phosphorylated on Thr642 in JJN3, KMS11,
L363, and RPMI8226 cells (Figure 2B) under basal con-
ditions. Thr642 is a residue known to be phosphorylated
by AKT [3] during insulin stimulation in myocytes and
adipocytes, and necessary for maintenance of GLUT4 ac-
tivity and whole-body glucose homeostasis in mice [10].
We then examined the effects of expressing full-length
AS160 and impairing AS160 phosphorylation on GLUT4
trafficking by testing the well-characterized AS160-4P
mutant [1]. To avoid the potentially confounding effects
of endogenous AS160_v2 protein, we selected MM.1S
cells for these studies based on their low baseline AS160expression. MM.1S cells were transiently transfected with
the AS160-4P construct, which contains alanine substi-
tutions at four critical phosphorylation sites required for
GLUT4 trafficking to the surface or an empty vector [1].
Cells were then stained for GLUT1 and GLUT4 and vi-
sualized via confocal immunofluorescence microscopy to
evaluate subcellular localization profiles. Since GLUT1 is
constitutively localized on the PM [9], it serves as a mark-
er for PM bound proteins as well as a negative control,
as it remains unchanged upon introduction of AS160-
4P (Figure 2C). In contrast, AS160-4P-expressing MM.1S
cells revealed an intracellular sequestration of GLUT4,
based on discrete, punctate cytosolic staining which con-
trasts with that observed in cells transfected with control
pcDNA (Figure 2C). These results demonstrate that ectopic
Cheng et al. Cancer & Metabolism 2013, 1:14 Page 4 of 8
http://www.cancerandmetabolism.com/content/1/1/14expression of a full-length, phospho-deficient AS160 mu-
tant is sufficient to impair constitutive GLUT4 cell surface
residence, which is characteristic of MM cells [9].
Suppression of AS160_v2 expression decreases glucose
consumption and proliferation by reducing GLUT4 PM
content
Cell lines that basally up-regulate AS160_v2 (KMS11, JJN3,
and L363) were stably transduced with pLKO.1 lentiviral
vectors expressing shRNAs specific to AS160 (AS-1, AS-2)
or noncoding control (C). The loss of AS160_v2 protein
(Figure 3A) universally reduces glucose consumption three
days post-infection (Figure 3B, D and F). Inhibition of glu-
cose transport by AS160_v2 silencing is associated with
cytotoxic effects in KMS11 and L363 cell lines and reduces
cell growth in JJN3 cells (Figure 3C, E and G). Expression
of an alternative AS160 shRNA (labeled AS-2) also reduces
glucose uptake and induces cell death (Figure 3B-C). PM
proteins were extracted from JJN3 cells expressing C and
AS-1 shRNAs to correlate GLUT4 PM localization with
the expression of AS160-V2. Immunoblot analysis demon-
strated reduced GLUT4 content on the cell surface in cells
expressing the AS-1 shRNA, while whole-cell GLUT4
levels remained constant (Figure 3H-I). The outcomes of
RNAi experiments performed in the KMS11, JJN3, and
L363 cell lines show that AS160_v2 silencing closely re-
capitulates the effects of GLUT4 suppression and glucose
deprivation, with KMS11 and L363 cells undergoing
substantial cell death in response to these perturbations
while JJN3 cells consistently display a growth defect with
maintained viability [9]. As an additional negative control,
we transduced U266 cells with C and AS-1 shRNAs. Since
U266 cells express very low levels of AS160_v2, there is
no impact on glucose uptake or cell growth (Figure 3J-K).
Conclusions
In sum, we have elucidated a novel mechanism through
which MM cells achieve constitutive GLUT4 activation
to promote the Warburg effect. Our findings corrobor-
ate those described by Baus and colleagues regarding
the stimulatory function displayed by phosphorylated
AS160_v2 towards GLUT4 trafficking [5]. In their study,
the authors demonstrate that ectopic expression of human
AS160_v2 cDNA in AS160-negative L6 rat myoblast cells
potentiates GLUT4 cell surface localization and cellular
2-deoxy-D-glucose uptake in a signaling-dependent man-
ner. It has also been shown that GLUT4 translocation is
suppressed in insulin-treated 3T3-L1 adipocytes following
RNAi-mediated silencing of full-length AS160 [11,12].
In line with these in vitro findings, a loss-of-function
nonsense mutation in the TBC1D4 gene in a severely
insulin-resistant Acanthosis nigricans patient was reported
[13]. Interestingly, expression of the resulting truncated
AS160 protein (R363X) in 3T3-L1 adipocytes recapitulatedthe aberrations associated with AS160 silencing, thus
connecting impaired AS160 function with diminished
GLUT4 activity under insulin-replete conditions.
More recently, studies in adipocytes and soleus isolated
from AS160−/− mice demonstrated impaired insulin stim-
ulated glucose uptake and reduced insulin-stimulated
GLUT4 PM translocation [14]. Interestingly, the AS160−/−
adipocytes and soleus also exhibited reduced GLUT4 con-
tent suggesting a potential role for AS160 in regulating
insulin-sensitivity by modulation of GLUT4 content [14].
These studies strongly support a model of AS160 function
in which both full-length AS160 and AS160_v2, when
phosphorylated, augment the actions of insulin to pro-
mote GLUT4 cell surface localization. We hypothesize,
however, that under identical, stimulatory signaling condi-
tions (e.g., insulin receptor activation), AS160_v2 more
robustly promotes GLUT4 trafficking in comparison to
full-length AS160. This hypothesis is based on the findings
that the fractional increase observed in insulin-stimulated
2-DG uptake by L6 myotubes overexpressing AS160_v2
[5] is greater than the fractional decline in insulin stimu-
lated 2-DG transport by 3T3-L1 adipocytes displaying
knockdown of full-length AS160 [12]. We acknowledge,
however, that further studies comparing these two splice
variants under identical experimental conditions are ne-
cessary to extract meaningful information regarding their
distinct functionalities. Furthermore, interrogation of the
functional consequences of inclusion of exons 11 and 12
in the AS160 protein is paramount to understanding the
differences between isoforms.
While the biological functions of the additional AS160
truncated transcripts detected in NBL and MM patient
samples are unknown, one can speculate that possible
maintenance of Rab-GAP activity in these transcripts
may increase retention of GLUT4 or regulate the pro-
pensity of GLUT4 PM trafficking in response to stimu-
latory signals. Since insulin and IGF-1 are important
myeloma growth factors [15,16] there may exist a se-
lective pressure in MM to upregulate genes that couple
insulin/IGF-1 signaling to metabolic effectors that pro-
mote aerobic glycolysis.
We have previously demonstrated that some MM cell
lines, like MM.1S and U266, exhibit constitutive GLUT4
cell surface localization even in the absence of AS160
expression [9], supporting investigation of alternative,
AS160-independent mechanisms of GLUT4 activation
in MM. One remaining unresolved issue pertains to the
identity of the kinases responsible for AS160 phosphor-
ylation in the context of myeloma. Given a recent report
detailing the widespread detection of tumor-specific
AS160 phosphorylation in breast cancer biopsies [17],
investigation of the AS160/GLUT4 axis and further
identification of the upstream activating kinases in
tumor cells will serve to clarify the role of AS160
Figure 3 (See legend on next page.)
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Figure 3 AS160 knockdown suppresses glucose consumption and inhibits cell growth by reducing PM GLUT4 content in KMS11, JJN3,
and L363 but not in U266 cells. (A) Immunoblot analysis verifying AS160 knockdown with two distinct AS160 targeting shRNA’s. Image
representative of three individual repeats is presented; (B, D and F) Glucose uptake rates in KMS11, JJN3, and L363 cells, respectively, containing
non-target control, AS-1 and AS-2 shRNAs. Rates were determined at 0 and 5 h after incubation in 5 mM glucose; (C, E and G) Growth rates in
KMS11, JJN3, and L363 cell lines containing non-target control, AS-1 and AS-2 shRNAs, show trypan blue excluded viable cell counts at 0, 3, 4,
and 5 days; (H) Immunoblot analysis of plasma membrane proteins from JJN3 cells infected with non-target control and AS-1 shRNAs for GLUT4
and Na/K and α-tubulin loading controls; (I) Immunoblot analysis for AS160, GLUT4, and GAPDH loading control from whole cell lysates in JJN3
cells treated with non-target control and AS-1 shRNAs. Immunoblots are representative of two individual repeats; (J) Glucose uptake rates in U266
containing non-target control and AS-1 shRNA; (K) Growth rates in U266 containing non-target control and AS-1 shRNAs, show trypan blue
excluded viable cell counts at 0, 3, and 4 days. Bars and points represent mean ± SD of three repeats; *P <0.05, **P <0.01, ***P <0.001.
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MM.1S (generated in our laboratory), KMS11, JJN3,
L363, H929, and INA6 (provided by Dr. M. Kuehl (NCI,
Bethesda, MD), and RPMI8226 and U266 cell lines
American Type Culture Collection (ATCC), VA, U.S.A
were cultured in RPMI 1640 (Invitrogen) supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100
U/mL pen/strep, and 2.5 μg/mL Amphotericin B at 37°C
in 5% CO2.
B cell isolation
Normal B lymphocytes were purified from peripheral
blood mononuclear cells using the EasySep™ Negative
Selection Human B Cell Enrichment Kit (STEMCell
Technologies, BC, Canada) as previously described [9].
RNA extraction
RNA was extracted from MM cell lines and normal B
lymphocytes using RNeasy™ Mini Kit (Qiagen) per man-
ufacturer’s instructions.
Reverse transcription of RNA extracts and relative
quantitative real time PCR
Total RNA isolated from cell lines and normal B lympho-
cytes was transcribed into cDNA using Multiscribe™ Re-
verse Transcriptase (Applied Biosystems) according to the
manufacturer’s instructions. Quantitative RT-PCR experi-
ments were performed on an ABI 7900HT Fast Real-Time
PCR system (ABI) using the Taqman Universal Master
Mix (ABI). YWHAZ, RPL13A, and EIF4A primer/probe
sets (Primerdesign Ltd, U.K) were used as endogenous
controls across MM cell lines. Primer/probe sets specific
for Exon 1 and Exons 5–7 of AS160 (ABI) were used for
relative quantification of AS160 transcript levels across
MM cell lines.
Sequencing the AS160.V2 junction
The following primers were used for PCR amplification
and sequencing of the AS160.V2 junction and span aregion 137 bp upstream and 219 bp downstream of Exon
11 and 12 AS160_v2 deletion: FWD – AS160_Junction,
5′ – AACGTTTCCCGAAGAGGATTCCGA – 3′ and
REV-AS160_Junction, 5′–ACAGGAATACAACCAGCG
GTTCCT–3′ (Integrated DNA Technologies). cDNA
from MM lines and NBLs were subjected to PCR am-
plification. A vector containing full-length AS160 (FL-
AS160) (kindly provided by Dr. G Lienhard, Dartmouth
College, NH) was used as a positive control and ampli-
fied with one round of PCR. For each round, 800 ng
cDNA and 50 ng vector DNA were amplified under the
following conditions: 1× Thermopol buffer (containing
20 mM Tris–HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2
mM MgSO4, 0.1% Triton X-100, pH 8.8 at 25°C), 0.8
mM total dNTPs, 100 ng primers, and 2 U Vent Poly-
merase (New England Biolabs). DNA was subjected to
PCR conditions as follows: 30 cycles of denaturing at
95°C for 30s, primer annealing at 52°C for 30s, exten-
sion at 72°C for 1 minute, and final extension at 72°C
for 10 minutes. DNA fragments were analyzed by agar-
ose gel electrophoresis, excised using a Gel Extraction
Kit (Qiagen) and sequenced with same PCR primers
using an ABI 3730 High-Throughput DNA Sequencer
(Applied Biosystems) (Center for Genetic Medicine,
Northwestern University).
Protein extraction
Whole cell protein lysates were prepared as previously
described [9]. Plasma membrane proteins were extracted
from 50 × 106 cells homogenized at 30 Hz for 3 minutes
using TissueLyser LT (Qiagen) and plasma membrane
proteins were extracted using the Plasma Membrane
Protein Extraction Kit (BioVision) according to the man-
ufacturer’s instructions.
RNA-Seq
mRNA-Seq sequencing of the JJN3 MM cell line yielded
49 million tags. The data was mapped onto the human
genome, build UCSC hg19/NCBI 37, with the suite of
tools bowtie2 and tophat2 [18,19]; 40 million tags were
aligned onto the reference genome (81% mapping ratio).
Transcript abundance was assessed using cufflinks and the
GENCODE [20] gene definition version 14.0; GENCODE
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variants of TBC1D4. Access to Multiple Myeloma Re-
search Consortium patient sample and cell line RNA-Seq
data sets were obtained from Dr. Jonathan Keats, TGen.
NBL RNA-Seq data sets were obtained from the NCBI
Gene Expression Omnibus (GEO) repository.
SDS-PAGE and immunoblot analysis
Extracted proteins were separated by SDS-PAGE using
Novex 8-16% Tris-glycine Mini gels (Invitrogen) or 4-15%
Mini-Protean TGX Precast Gels (Bio-Rad) and transferred
onto nitrocellulose or PVDF membranes and detected by
Amersham™ ECL Plus Western Blotting Reagents (GE
Healthcare), as previously described [9]. The following pri-
mary antibodies were used: α-tubulin (Santa Cruz Bio-
technology Inc.), total AS160 anti-serum (Millipore), pThr
642 AS160 (Invitrogen), GAPDH (Santa Cruz Biotechnol-
ogy), GLUT4 anti-serum (provided by Dr. S. Cushman,
National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD), Na+/K+ ATPase Plasma Mem-
brane Marker (Abcam), secondary mouse and rabbit
antibodies conjugated to horseradish peroxidase (Cell
Signaling Technology).
Transient transfection into MM.1S
MM.1S cells were co-transfected with either empty
pcDNA vector or a full length AS160-4P (FL AS160-4P)
construct (Dr. G. Lienhard, Dartmouth college, NH) and
a GFP expressing plasmid (pmax GFP™ plasmid, Amaxa)
using the Amaxa Nucleofector Kit V and the Amaxa
Nucleofector 2b Device, with program O23 (Lonza) per
manufacturer’s instructions. After 48 h of culture GFP
positive cells were sorted on a Beckman Coulter MoFlo™
XDP Cell Sorter.
Immunofluorescence microscopy
Cells were washed in PBS and spun onto microscope
slides (Shandon Cytoslide) using a Shandon Cytospin
centrifuge (Thermo Fischer Scientific). Slides were fixed
in 4% freshly prepared paraformaldehyde at pH 7.4,
permeabilized with 0.03% saponin in PBS, and incu-
bated with blocking buffer (10% normal goat serum
containing 0.03% saponin). Cells were stained with anti-
GLUT1 (Abcam) or anti-GLUT4 (Dr. S. Cushman,
NIDDK, MD) and secondary antibodies in blocking buf-
fer for 1 h at room temperature as previously described
[9]. Cells were visualized at 63× (1.4 NA) oil objective
with an LSM-510 Meta, Carl Zeiss confocal microscope.
Image analysis was performed using the Zeiss Axio vi-
sion LE image browser.
Lentiviral production and transduction in MM cell lines
Non-targeting CshRNA and AS160 shRNA pLKO.1 vec-
tors (Sigma) were packaged and lentivirus generated asdescribed previously [9]. Cells were selected in Puromycin
(KMS11, 0.3 μg/mL; L363, 0.5 μg/mL; JJN3, 0.25 μg/mL;
U266, 0.25 μg/mL), two days post-infection.
Cell growth assay
Three days post-infection (day 0), an equal number of
cells were plated in T25 flasks. For 0, 3, 4, and 5 day
time points, cells were harvested and viable cell count
was determined by Trypan Blue exclusion using Vi-Cell
Viability Analyzer (Beckman-Coulter).
Glucose consumption assay
The rate of glucose uptake was determined three days
post-infection in cells incubated in 5 mM glucose RPMI
1640 medium for 5 h in a 37°C incubator with 5% CO2.
The concentration of glucose was detected in media
obtained at 0 and 5 h using the Amplex Red™ Glucose/
Glucose Oxidase Assay Kit (Invitrogen) according to the
manufacturer’s instructions.
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